Insider-Trading
Aktuelle Insider-Transaktionen (SEC Form 4) — Käufe und Verkäufe von Vorständen, Direktoren und Großaktionären.
| Ticker | Insider | Funktion | Datum | Transaktion | Kurs ($) | Stück | Wert ($) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| DGX | Pfeiffer Gary M | Director | 26.10.2026 | Verkauf | 243,00 | 1.203 | 292.329 | Form 4 |
| DGX | Carter Robert B | Director | 21.10.2026 | L | 235,93 | 10 | 2.359 | Form 4 |
| DGX | Samad Sam | Executive Vice President & CFO | 21.10.2026 | Zuteilung | 235,94 | 90 | 21.235 | Form 4 |
| DGX | Gregg Vicky B | Director | 21.10.2026 | Zuteilung | 235,94 | 63 | 14.864 | Form 4 |
| DGX | Kuppusamy Karthik | SVP, Clinical Solutions | 21.10.2026 | L | 235,94 | 33 | 7.786 | Form 4 |
| DGX | Lassiter Wright III | Director | 21.10.2026 | L | 235,96 | 6 | 1.416 | Form 4 |
| DGX | Plewman Patrick | SVP for Diagnostic Services | 21.10.2026 | L | 235,94 | 41 | 9.674 | Form 4 |
| DGX | Main Timothy L | Director | 21.10.2026 | L | 235,94 | 18 | 4.247 | Form 4 |
| DGX | Delaney Mark E | SVP & Chief Commercial Officer | 21.10.2026 | L | 235,94 | 25 | 5.899 | Form 4 |
| DGXX | Amar Michel | Chief Executive Officer | 14.10.2026 | Kauf | 2,76 | 20.000 | 55.256 | Form 4 |
| DGX | Davis J. E. | CEO and President | 01.09.2026 | Verkauf | 242,72 | 10.000 | 2.427.200 | Form 4 |
| DGX | Prevoznik Michael E | SVP & General Counsel | 28.08.2026 | Schenkung | — | 1.000 | — | Form 4 |
| DGX | Prevoznik Michael E | SVP & General Counsel | 28.08.2026 | Verkauf | 244,51 | 430 | 105.141 | Form 4 |
| DGX | Prevoznik Michael E | SVP & General Counsel | 28.08.2026 | Verkauf | 243,63 | 6.237 | 1.519.505 | Form 4 |
| DGX | Prevoznik Michael E | SVP & General Counsel | 28.08.2026 | Verkauf | 242,88 | 16.010 | 3.888.437 | Form 4 |
| DGX | Prevoznik Michael E | SVP & General Counsel | 28.08.2026 | Optionsausübung | 112,17 | 22.677 | 2.543.679 | Form 4 |
| DGXX | Amar Alec | President | 20.08.2026 | Kauf | 3,86 | 10.000 | 38.600 | Form 4 |
| DGXX | Amar Michel | Chief Executive Officer | 19.08.2026 | Kauf | 3,60 | 20.000 | 72.000 | Form 4 |
| DGX | Delaney Mark E | SVP & Chief Commercial Officer | 28.07.2026 | Verkauf | 235,18 | 1.600 | 376.288 | Form 4 |
| DGX | Kuppusamy Karthik | SVP, Clinical Solutions | 22.07.2026 | L | 206,81 | 37 | 7.652 | Form 4 |
| DGX | Carter Robert B | Director | 22.07.2026 | L | 206,80 | 11 | 2.275 | Form 4 |
| DGX | Gregg Vicky B | Director | 22.07.2026 | Zuteilung | 206,81 | 72 | 14.890 | Form 4 |
| DGX | Plewman Patrick | SVP for Diagnostic Services | 22.07.2026 | L | 206,81 | 46 | 9.513 | Form 4 |
| DGX | Main Timothy L | Director | 22.07.2026 | L | 206,81 | 21 | 4.343 | Form 4 |
| DGX | Samad Sam | Executive Vice President & CFO | 22.07.2026 | Zuteilung | 206,81 | 102 | 21.094 | Form 4 |
| DGX | Lassiter Wright III | Director | 22.07.2026 | L | 206,81 | 6 | 1.241 | Form 4 |
| DGX | Delaney Mark E | SVP & Chief Commercial Officer | 22.07.2026 | L | 206,81 | 34 | 7.031 | Form 4 |
Kompakter Markt-Überblick — keine Anlageberatung. Quelle: Fundamentaldaten & SEC-Berichte (Geschäfts- und Quartalsberichte, 10-K/10-Q).